Please assess the completion status of the following clinical trial:

Trial Title: Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed prostate adenocarcinoma~* Bone metastases confirmed by bone scan~* Current androgen deprivation therapy~* Castration-resistant disease based on progression in bone and/or PSA progression~* Recovered from toxicities related to prior treatment, except alopecia, lymphopenia, other non-clinically significant adverse events~* Life expectancy of greater than 3 months~* Normal organ and marrow function~* Capable of understanding and complying with the protocol requirements~* Agree to use medically accepted methods of contraception~* Able to swallow capsules~Exclusion Criteria:~* More than two prior chemotherapy regimens for metastatic prostate cancer~* Known untreated, symptomatic or uncontrolled brain metastases~* Serious or unhealed wound~* Treatment with anticoagulants~* Previously identified allergy or hypersensitivity to components of the study treatment formulation~* History of a different malignancy unless disease-free for at least 5 years, or basal or squamous cell carcinoma of the skin~* Current antiretroviral therapy~* Uncontrolled hypertension~* Uncontrolled intercurrent illness

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Dose level 0: cabozantinib 40 mg daily
- Cohort 2 (Type: EXPERIMENTAL): Dose level -1: cabozantinib 20 mg daily
- Expansion cohort (Type: EXPERIMENTAL): Dose level 0: cabozantinib 40 mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).